Final Results of DREAMM-2 Show Durable Responses With Belantamab Mafodotin
Final results from the DREAMM-2 trial suggest that belantamab mafodotin produces durable responses in patients with relapsed/refractory multiple myeloma.
Final results from the DREAMM-2 trial suggest that belantamab mafodotin produces durable responses in patients with relapsed/refractory multiple myeloma.
Researchers sought to determine rates of infections for patients with multiple myeloma receiving autologous transplantation in India compared to other countries.
Researchers sought to determine survival outcomes of ASCT in patients with multiple myeloma who had a suboptimal response to induction therapy.
Researchers sought to determine the allocation and cost involved with CAR-T therapy for patients with multiple myeloma.
Aphexda is expected to be available in September 2023.
Researchers sought to assess and better characterize the risk of infection in patients with MM treated with bispecific antibodies.
Researchers sought to determine whether screening patients with MM after ASCT with FDG-PET would be able to identify patients with residual disease.
Researchers sought to determine whether carfilzomib- or pomalidomide-based therapeutic regimens would improve survival in MM following daratumumab.
Melflufen plus daratumumab and dexamethasone produced better outcomes than daratumumab alone in a phase 3 trial of patients with relapsed/refractory multiple myeloma.
Researchers sought to determine whether a double-sided approach to engineered CAR-T therapy may help to prevent immune escape in patients with multiple myeloma.